141 related articles for article (PubMed ID: 38604728)
1. There and Back Again: A Perspective on 20 Years of CYP4Z1.
Kowalski JP; Rettie AE
Drug Metab Dispos; 2024 May; 52(6):498-507. PubMed ID: 38604728
[TBL] [Abstract][Full Text] [Related]
2. CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer.
Yang X; Hutter M; Goh WWB; Bureik M
Curr Pharm Des; 2017; 23(14):2060-2064. PubMed ID: 28176668
[TBL] [Abstract][Full Text] [Related]
3. Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in
McDonald MG; Ray S; Amorosi CJ; Sitko KA; Kowalski JP; Paco L; Nath A; Gallis B; Totah RA; Dunham MJ; Fowler DM; Rettie AE
Drug Metab Dispos; 2017 Dec; 45(12):1364-1371. PubMed ID: 29018033
[TBL] [Abstract][Full Text] [Related]
4. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast.
Yan Q; Machalz D; Zöllner A; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2017 Dec; 146():174-187. PubMed ID: 28951277
[TBL] [Abstract][Full Text] [Related]
5. 1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1.
Qin H; Zhou Y; Liu H; Yuan Y; Guo Q; Yuan M; Xi T; Zhang Y
Environ Toxicol; 2024 Mar; 39(3):1505-1520. PubMed ID: 37994574
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.
Yu W; Chai H; Li Y; Zhao H; Xie X; Zheng H; Wang C; Wang X; Yang G; Cai X; Falck JR; Yang J
Toxicol Appl Pharmacol; 2012 Oct; 264(1):73-83. PubMed ID: 22841774
[TBL] [Abstract][Full Text] [Related]
7. Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
Kowalski JP; McDonald MG; Pelletier RD; Hanenberg H; Wiek C; Rettie AE
J Med Chem; 2020 May; 63(9):4824-4836. PubMed ID: 32302132
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
Machalz D; Li H; Du W; Sharma S; Liu S; Bureik M; Wolber G
Eur J Med Chem; 2021 Apr; 215():113255. PubMed ID: 33611185
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.
Al-Saraireh YM; Alshammari FOFO; Satari AO; Al-Mahdy YS; Almuhaisen GH; Abu-Azzam OH; Uwais AN; Abufraijeh SM; Al-Kharabsheh AM; Al-Dalain SM; Al-Qtaitat A; Al-Tarawneh F; Al Shuneigat JM; Al-Sarayreh SA
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143940
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.
Rieger MA; Ebner R; Bell DR; Kiessling A; Rohayem J; Schmitz M; Temme A; Rieber EP; Weigle B
Cancer Res; 2004 Apr; 64(7):2357-64. PubMed ID: 15059886
[TBL] [Abstract][Full Text] [Related]
11. HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1.
Liu H; Qin H; Zhou Y; Yuan Y; Liu Y; Chen Y; Yang Y; Ni H; Xi T; Zheng L
Mol Carcinog; 2021 Jun; 60(6):413-426. PubMed ID: 33866606
[TBL] [Abstract][Full Text] [Related]
12. CYP4Z1 3'UTR represses migration of human breast cancer cells.
Wang B; Zheng L; Chou J; Li C; Zhang Y; Meng X; Xi T
Biochem Biophys Res Commun; 2016 Sep; 478(2):900-7. PubMed ID: 27520371
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.
Khayeka-Wandabwa C; Zhao J; Pathak JL; Wu H; Bureik M
Breast Cancer Res Treat; 2022 Jan; 191(2):319-326. PubMed ID: 34725776
[TBL] [Abstract][Full Text] [Related]
14. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
15. Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1.
Du W; Machalz D; Yan Q; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2020 Apr; 174():113850. PubMed ID: 32044355
[TBL] [Abstract][Full Text] [Related]
16. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
Khayeka-Wandabwa C; Ma X; Cao X; Nunna V; Pathak JL; Bernhardt R; Cai P; Bureik M
Int Immunopharmacol; 2019 Aug; 73():64-71. PubMed ID: 31082724
[TBL] [Abstract][Full Text] [Related]
17. Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues.
Al-Saraireh YM; Alboaisa NS; Alrawashdeh HM; Hamdan O; Al-Sarayreh S; Al-Shuneigat JM; Nofal MN
Ecancermedicalscience; 2020; 14():1114. PubMed ID: 33144882
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Tarawneh F; Al-Sarayreh S; Almuhaisen GH; Satari AO; Al-Shuneigat J; Alrawashdeh HM
Breast Cancer (Dove Med Press); 2021; 13():565-574. PubMed ID: 34675653
[TBL] [Abstract][Full Text] [Related]
19. The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer.
Li C; Zheng L; Xin Y; Tan Z; Zhang Y; Meng X; Wang Z; Xi T
FEBS Lett; 2017 Apr; 591(7):991-1000. PubMed ID: 28236635
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization.
Yuan Y; Yao H; Zhou M; Ma X; Zhou Y; Xu J; Niu M; Yin J; Zheng L; Xu S
J Med Chem; 2022 Dec; 65(23):15749-15769. PubMed ID: 36414390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
